Back
Compare AU
Compare DRGN vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X China Tech ETF (DRGN) and the Betashares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRGN | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 161 | 72 |
Median incremental investment | $1,012.72 | $742.79 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,790.80 | $2,042.94 |
Average age group | > 35 | > 35 |
Key Summary
DRGN | DRUG | |
|---|---|---|
Strategy | DRGN.AX was created on 2025-05-06 by Global X. The fund's investment portfolio concentrates primarily on information technology equity. The investment objective of the Fund is to provide investors with a return that (before fees and expenses) tracks the performance of the Global X China Tech 20 Index (the Index). | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | East Money Information Co Ltd Class A (9.31 %) JD.com Inc Ordinary Shares - Class A (9.29 %) Tencent Holdings Ltd (9.19 %) | AUD - AUSTRALIA DOLLAR (0 %) BRL - BRAZILIAN REAL (0 %) CHF - SWISS FRANC (0 %) |
Top 3 industries | Information Technology (49.65 %) Consumer Discretionary (17.81 %) Financials (11.33 %) | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) |
Top 3 countries | China (100.00 %) | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) |
Management fee | 0 % | 0.57 % |
Key Summary
DRGN | DRUG | |
|---|---|---|
Issuer | Global X | BetaShares |
Tracking index | Global X China Tech 20 Index - AUD - Benchmark TR Net | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0 % | 0.57 % |
Price | $12.18 | $8.70 |
Size | $85.696 million | $183.805 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 5.29 % | 1.82 % |
Market | ASX | ASX |
First listed date | 07/05/2025 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRGN | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 161 | 72 |
Median incremental investment | $1,012.72 | $742.79 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,790.80 | $2,042.94 |
Average age group | > 35 | > 35 |
Pros and Cons
DRGN | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRGN | DRUG |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |